Subcutaneous Vedolizumab Treatment in a Real-World Inflammatory Bowel Disease Cohort Switched From Intravenous Vedolizumab: Eighteen-Month Prospective Follow-up Study
PMID: 38544907
Source: Crohns Colitis 360
Publication date:
2025-07-24
Year:
2024
Abstract
NULL